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AbstrACt
Mice with genetic inhibition (AC3‑I) of the multifunctional Ca2+/calmodulin dependent 
protein kinase II (CaMKII) have improved cardiomyocyte survival after ischemia. Some K+ 
currents are up‑regulated in AC3‑I hearts, but it is unknown if CaMKII inhibition increases 
the ATP sensitive K+ current (IKATP) that underlies ischemic preconditioning (IP) and confers 
resistance to ischemia. We hypothesized increased IKATP was part of the mechanism for 
improved ventricular myocyte survival during ischemia in AC3‑I mice. AC3‑I hearts were 
protected against global ischemia due to enhanced IP compared to wild type (WT) and 
transgenic control (AC3‑C) hearts. IKATP was significantly increased, while the negative 
regulatory dose‑dependence of ATP was unchanged in AC3‑I compared to WT and 
AC3‑C ventricular myocytes, suggesting that CaMKII inhibition increased the number of 
functional IKATP channels available for IP. We measured increased sarcolemmal Kir6.2, 
a pore‑forming IKATP subunit, but not a change in total Kir6.2 in cell lysates or single 
channel IKATP opening probability from AC3‑I compared to WT and AC3‑C ventricles, 
showing CaMKII inhibition increased sarcolemmal IKATP channel expression. There were 
no differences in mRNA for genes encoding IKATP channel subunits in AC3‑I, WT and 
AC3‑C ventricles. The IKATP opener pinacidil (100 mM) reduced MI area in WT to match 
AC3‑I hearts, while the IKATP antagonist HMR1098 (30 mM) increased MI area to an 
equivalent level in all groups, indicating that increased IKATP and augmented IP are 
important for reduced ischemic cell death in AC3‑I hearts. Our study results show CaMKII 
inhibition enhances beneficial effects of IP by increasing IKATP.
INtrOduCtION
Chronic	inhibition	of	the	multifunctional	Ca2+/calmodulin-dependent	protein	kinase	
II	 (CaMKII)	 in	 cardiomyocytes	 significantly	 reduces	 maladaptive	 remodeling	 after	
myocardial	 infarction	 (MI).1	 CaMKII	 inhibition	 can	 prevent	 adverse	 remodeling	 after	









required	 for	 IP	and	 increased	 IKATP	activity	 facilitates	 IP	 to	 reduce	MI	size	 in	 response	
to	 ischemia-reperfusion	 injury.6-8	Two	protein	subunits,	Kir	6.2	and	SUR2A,	 function-
ally	 and	 physically	 interact	 to	 produce	 a	 pharmacological	 and	 biophysical	 profile	 that	
closely	resembles	the	cardiac	sarcolemmal	IKATP.
9	Under	normal	conditions,	sarcolemmal	
IKATP	 channels	 are	 predominantly	 closed,	 however,	 during	 a	metabolic	 insult,	 such	 as	
cardiac	ischemia,	IKATP	channels	are	activated	and	protect	the	myocardium	from	death.	
We	 hypothesized	 that	 CaMKII	 inhibition	 might	 increase	 IKATP	 and	 thereby	 improve	
	myocardial	survival	after	ischemia.
Here	 we	 show	 that	 Langendorff-perfused	 mouse	 hearts	 with	 CaMKII	 inhibition	
produced	by	 transgenic	 expression	of	 a	 specific	CaMKII	 inhibitory	peptide	 (AC3-I)1-4	
were	 resistant	 to	 ischemia-reperfusion	 injury	 and	 showed	 enhanced	 protection	 from	
IP	 compared	 to	 transgenic	 animals	 expressing	 a	 control	 peptide	 (AC3-C)	 and	 to	wild	
type	 (WT)	 littermate	 controls.	Excised	 cell	membrane	patches	 from	AC3-I	 ventricular	
myocytes	 had	 significantly	 increased	 IKATP	 current	 density	 and	 greater	 sarcolemmal	
CaMKII,	Ischemic	Preconditioning	and	IKATP
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expression	 of	 Kir6.2,	 the	 pore	 forming	 subunit	 of	 the	myocardial	
IKATP
10	 than	 controls.	 However,	 IKATP	 channel	 opening	 prob-
ability	was	 equivalent	 in	 cell	membrane	patches	 from	AC3-I,	WT	
and	 AC3-C	 ventricular	 myocytes.	 CaMKII	 inhibition	 increased	
the	 sarcolemmal	 density	 of	 functional	 IKATP	 channels,	 without	
affecting	the	inhibitory	effects	of	ATP	on	IKATP.	Treatment	with	the	
selective	 IKATP	antagonist	HMR	1098	 increased	 the	 infarct	 size	 in	
AC3-I	and	WT	littermate	control	mice	to	an	equivalent	level,	while	
the	 IKATP	 opener	 pinacidil	 reduced	MI	 size	 in	WT	mice	 to	 levels	
similar	 to	 those	 seen	 in	AC3-I	mice.	There	were	no	differences	 in	
total	 Kir6.2	 expression	 from	 ventricular	myocyte	 lysates	 or	 in	 the	
mRNA	 expression	 levels	 of	 genes	 encoding	 IKATP	 subunits	 from	
AC3-I,	WT	or	AC3-C	hearts,	indicating	that	up-regulation	of	IKATP	
during	CaMKII	inhibition	was	not	directly	related	to	enhanced	gene	
transcription	 or	 protein	 translation	 of	 the	 channel	 subunits.	 Our	






Ethical approval.	 All	 experiments	 were	 performed	 under	 the	
approval	 of	 the	 University	 of	 Iowa	 Institutional	 Animal	 Care	
Committee.	The	investigation	conforms	to	the	Guide for the Care and 
Use of Laboratory Animals published	by	the	US	National	Institutes	of	
Health	(NIH	Publication	No.	85-23,	revised	1996).
Mice with myocardial CaMKII inhibition.	 The	 AC3-I	 and	
AC3-C	mice	 were	 generated	 by	 synthesis	 of	 a	minigene	 based	 on	





Electrophysiology.	 Mice	 were	 sacrificed	 after	 deep	 anesthesia	
with	 2.5%	Avertin	 at	 a	 dose	 of	 20	ml/g	 [10	 g	 of	 tribromoethanol	




described.11	 IKATP	 from	 ventricular	 myocytes	 was	 recorded	 using	
inside-out	patch-clamp	configuration	of	the	patch-clamp	technique	
as	 described.12	Tip	 resistance	was	 1.4–1.8	Mo	when	 pipettes	were	
filled	with	intracellular	solution,	and	series	resistance	compensation	
was	 routinely	 set	 at	 >85%	 in	 all	 experiments.	 All	 recordings	 were	
obtained	at	room	temperature	(22–26°C).	GFP	fluorescence	was	visu-
alized	in	cells	excited	by	high-power	Hg-lamp	(Nikon	Instruments).	
Standard	 bath	 (intracellular)	 and	 pipette	 (extracellular)	 solution	











where	 Irel	 is	 the	 relative	 current,	K1/2	 is	 the	 concentration	 causing	
half-maximum	blockade,	and	H	is	the	Hill	coefficient.
Single	 channel	 IKATP	 recordings	were	 obtained	 from	 inside	 out	
patches	 using	 fire-polished	 pipettes,	 (resistance	 ~7–10-Mo),	 when	
filled	 with	 pipette	 solution	 containing	 (mM):	 140	 KCl,	 1	 CaCl2,	
1	MgCl2,	 5	HEPES-KOH,	 pH	7.3.	Cardiac	 cells	were	 superfused	
with	 intracellular	 solution	 containing	 (mM):	 140	 KCl,	 1	 MgCl2,	
5	EGTA,	 5	 HEPES-KOH,	 pH	 7.3,	 in	 the	 absence	 or	 presence	
of	 ATP,	 and	 recordings	 made	 at	 room	 temperature	 (20–26°C)	 as	






of	 KATP	 channels	 was	 set	 at	 half	 of	 the	 single	 channel	 amplitude.	




for	measuring	myocardial	 viability	 and	heart	 function.4	Mice	were	
anesthetized	with	avertin	and	hearts	were	quickly	excised	and	rinsed	
in	 iced	Tyrode’s	 solution	containing	 (in	mM):	137	NaCl,	5.4	KCl,	
0.5	MgCl2,	 0.16	 NaH2PO4,	 3	 NaHCO3,	 5	 HEPES-NaOH,	 and	
Heparin	1	mg/10ml,	which	was	previously	adjusted	to	a	pH	of	7.4	
with	NaOH	at	room	temperature.	Excess	tissue	was	dissected	away.	
Hearts	 were	 immediately	 perfused	 retrogradely	 through	 the	 aorta	
for	 1–2	 minutes	 at	 room	 temperature	 with	 Hanks’	 balanced	 salt	
solution	 (GIBCO,	Cat	No.	14025-092)	 and	mounted	on	 a	modi-
fied	 Langendorff	 apparatus	 (HSE-HA	 perfusion	 systems,	 Harvard	
Apparatus)	 for	 retrograde	aortic	perfusion	at	a	constant	pressure	of	
80	mmHg	with	carbogen	(95%	O2,	5%	CO2)	and	Krebs-Henseleit	
bicarbonate	 (KHB)	 solution	 consisting	 of	 (in	mM):	 25	NaHCO3,	
118	 NaCl,	 4.7	 KCl,	 1.2	 MgSO4,	 1.2	 NaH2PO4,	 2.5	 CaCl2,	
0.5	Na-EDTA,	 15	 Glucose,	 Pyruvate	 2,	 with	 pH	 equilibrated	 to	
7.4.	The	 perfused	 heart	 was	 immersed	 into	 the	 water-jacked	 bath	
and	 was	 maintained	 at	 36°C.	 A	 polyethylene	 balloon	 filled	 with	
ddH2O	was	 inserted	 into	 the	 cavity	of	 left	 ventricle	 through	a	 left	
atrial	 incision.	After	allowing	 the	heart	 to	 stabilize	 for	16	minutes,	
IP	with	two	2	min	cycles	of	global	ischemia	were	followed	by	5	min	
of	reperfusion.	Some	hearts	had	30	min	of	stabilization	with	no	IP.	




Measurement of MI size.	 At	 the	 end	 of	 ischemia/reperfusion,	
each	heart	was	 removed	 from	 the	Langendorff	perfusion	apparatus	
and	 immediately	 frozen.	The	 frozen	 hearts	 were	 cut	 from	 apex	 to	
base	 into	 eight	 transverse	 slices	 of	 approximately	 equal	 thickness	
(~0.8	mm).	The	slices	were	placed	into	a	small	cell	culture	dish	and	














Immunoblots.	 Following	 dissociation	 of	 ventricular	 myocytes	
from	 adult	WT,	 AC3-I	 and	 AC3-C	mice,	 whole	 cell	 lysates	 were	
prepared	 as	 described.15	 Protein	 concentrations	 were	 determined	







Surface biotinylation assays.	 Freshly	 isolated	 ventricular	
	cardiomyocytes	were	incubated	at	4°C	to	inhibit	membrane	protein	
internalization	 and	 labeled	 with	 NHS-biotin.	 The	 biotinylation	
reactions	 were	 quenched	 and	 cells	 were	 washed	 and	 collected.	
Detergent-soluble	lysates	were	prepared	and	biotinylated	membrane	
surface	 proteins	 were	 affinity-purified	 using	 streptavidin-conju-
gated	 sepharose.	 Purified	 membrane	 proteins	 were	 analyzed	 by	
SDS-PAGE	and	 immunoblot	using	Kir6.2	or	Na+/Ca2+	 exchanger	
(NCX)-specific	antibody.
RNA preparation.	 Hearts	 were	 excised	 from	 10–12	 week-old	
male	 and	 female	 WT	 mice	 and	 from	 mice	 expressing	 either	 the	
CaMKII	AC3-I	(AC3-I)	or	AC3-C	(AC3-C)	peptide	(n	=	6	in	each	
group).	All	 animals	were	 sacrificed	by	 cervical	dislocation,	 and	 the	
hearts	 were	 rapidly	 removed.	 Ventricles	 were	 dissected	 from	 each	
heart	and	flash-frozen	in	liquid	nitrogen	for	further	RNA	isolation.	
Total	RNA	was	isolated	and	DNase	treated	using	the	RNeasy	Fibrous	
Tissue	Mini	 Kit	 (Qiagen).	The	 quality	 of	 total	 RNA	was	 assessed	
by	 gel	 electrophoresis.	Genomic	DNA	 contamination	was	 assessed	








(Applied	Biosystems).	The	 384	wells	 of	 each	 array	were	 preloaded	
with	 96	 x	 4	 predesigned	FAM-labeled	 fluorogenic	TaqMan	probes	
and	primers.	The	probes	were	 labeled	with	the	 fluorescent	reporter	
dye	 6-carboxyfluorescein	 (FAM®,	 Applera	 Corporation)	 on	 the	 5'	





(n	 =	 7).	These	 genes	 were	 analyzed	 simultaneously,	 together	 with	
(n	=	4)	control	genes	used	for	normalization.	Two	ng	of	cDNA	from	
each	sample	was	combined	with	1X	TaqMan	Universal	Master	Mix	
(Applied	 Biosystems)	 and	 loaded	 into	 each	 well.	The	TLDA	were	
thermal-cycled	at	50°C	for	2	min	and	94.5°C	for	10	min,	followed	
by	 40	 cycles	 of	 97°C	 for	 30	 seconds	 and	 59.7°C	 for	 1	 minute.	
Data	 were	 collected	 with	 instrument	 spectral	 compensation	 using	
the	Applied	Biosystems	SDS	2.2.2	software	and	analyzed	using	the	
comparative	 threshold	 cycle	 (CT)	 relative	 quantification	method.
17	
The	 Hypoxanthine	 guanine	 Phosphoribosyl	 Transferase	 I	 (HPRT)	
gene	 was	 used	 as	 an	 endogenous	 control	 to	 normalize	 the	 data.	
Results	in	each	group	are	expressed	relative	to	HPRT.





CaMKII inhibition reduces myocardial infarction after ischemia 
and reperfusion.	 Langendorff-perfused	 hearts	 were	 subjected	 to	
global	 ischemia	 followed	 by	 reperfusion.	 Some	 hearts	 from	 each	
group	 (AC3-I,	 WT	 and	 AC3-C)	 were	 initially	 exposed	 to	 two	
episodes	of	IP	(Fig.	1A),	while	others	had	no	IP.	In	the	absence	of	IP,	
AC3-I	hearts	 showed	significantly	 less	 infarcted	 tissue	 than	AC3-C	
(p	<	0.001),	but	only	a	nonsignificant	trend	(p	=	0.13)	toward	less	
MI	than	WT	hearts	(Fig.	1C).	Resistance	of	AC3-I	and	WT	hearts	
to	 global	 ischemia-reperfusion	 injury	 was	 significantly	 enhanced	
by	 IP,	 compared	 to	 no	 IP.	 AC3-I	 hearts	 had	 significantly	 smaller	
MIs	(p	<	0.001)	after	IP	compared	to	WT	and	AC3-C	hearts	after	
IP	 (Fig.	 1B	 and	C).	These	 findings	 show	 that	CaMKII	 inhibition	
can	 augment	 the	 efficacy	of	 IP	 and	enhance	 resistance	 to	 ischemia	
induced	cardiomyocyte	death,	compared	to	wild-type	littermates	or	








myocytes,4	 we	measured	 IKATP	 to	 test	 if	 the	 increased	myocardial	
viability	after	ischemia-reperfusion	injury	in	AC3-I	hearts	was	asso-










IKATP	 in	 AC3-I	 ventricular	 myocytes	 is	 due	 to	 an	 increase	 in	 the	
number	of	functional	IKATP	channels	at	the	sarcolemma.




complex	 in	 heart	 (Fig.	 4).	 Immunoblotting	 revealed	 a	 significant	
increase	 in	 Kir6.2	 membrane	 surface	 expression	 in	 AC3-I	 cardio-
myocytes,	compared	with	WT	or	control	cardiomyocytes	(Fig.	4B).	
In	 contrast,	 AC3-I,	 WT	 and	 AC3-C	 myocytes	 had	 equivalent	
sarcolemmal	 expression	of	NCX1	 (Fig.	4B),	 consistent	with	 earlier	





genotypes	 (Fig.	 4A).	These	 data	 indicate	 that	 CaMKII	 inhibition	
enhances	 myocyte	 membrane	 surface	 expression	 of	 Kir6.2	 and	
suggest	that	a	previously	unrecognized	post-translational	mechanism	
is	important	for	increasing	IKATP	in	AC3-I	hearts.
CaMKII inhibition does not affect mRNA levels 
for IKATP encoding genes.	CaMKII	is	known	to	partici-
pate	 in	 gene	 transcription	 in	 heart.18	 On	 the	 other	
hand,	 AC3-I	 mice	 have	 increased	 K+	 currents	 by	 a	
mechanism	 that	 appears	 to	 be	 independent	 of	 changes	
in	transcription.4	Using	qRTPCR,	we	measured	mRNA	
expression	 levels	 of	 genes	 encoding	 SUR1	 (ABCC8),	
SUR2	(ABCC9),	Kir6.1	(KCNJ8)	and	Kir6.2	(KCNJ11),	
because	these	subunits	can	reconstitute	functional	IKATP	
channels.	 Specifically,	 KCNJ119	 and	 ABCC919	 are	
thought	to	encode	the	primary	components	of	myocar-
dial	IKATP	channels.	There	were	no	significant	differences	
in	 mRNA	 expression	 for	 these	 genes	 between	 AC3-I,	
WT	 or	AC3-C	 hearts	 (Fig.	 5).	These	 findings	 support	
the	 inference	 of	 our	 expression	 studies	 that	 CaMKII	
mediated	 increases	 in	 IKATP	 are	 due	 to	 a	 nontranscrip-
tional	mechanism	 (Fig.	4)	 and	are	 reminiscent	of	other	




Increased IKATP activity is the mechanism for resis‑
tance to ischemia in AC3‑I hearts.	 To	 determine	
directly	 if	 the	 increase	 in	 IKATP	 density	 observed	 in	
AC3-I	 ventricular	myocytes	 is	 responsible	 for	 ischemia	
resistance	in	AC3-I	hearts,	we	measured	MI	after	IP	and	
ischemia	reperfusion	in	the	presence	of	the	IKATP	agonist	
pinacidil.	 We	 reasoned	 that	 if	 increased	 IKATP	 was	 a	





WT	 hearts	 after	 IP	 seen	 in	 vehicle	 treated	 hearts.	 MI	
sizes	 were	 equivalent	 between	 AC3-I	 and	 WT	 hearts	
treated	 with	 pinacidil	 (Fig.	 6).	 These	 data	 suggested	
that	 increased	IKATP	 in	AC3-I	hearts	was	necessary	and	
possibly	 sufficient	 to	 account	 for	 the	 enhanced	 resis-
tance	 to	 MI	 after	 ischemia	 reperfusion	 injury.	 AC3-C	
hearts	did	not	show	a	significant	change	in	MI	size	after	
pinacidil,	consistent	with	earlier	findings	(Fig.	1C)	that	
AC3-C	 hearts	 had	 increased	 vulnerability	 to	 ischemic	
injury	and	were	unresponsive	to	IP.
We	 next	 tested	 the	 role	 of	 IKATP	 in	 IP	 by	 using	 an	
IKATP	 antagonist,	 HMR	 1098.	 We	 hypothesized	 that	
the	 benefit	 of	 CaMKII	 inhibition	 for	 enhancing	 IP	





responsive	 to	 HMR	 1098	 (p	 =	 0.09).	 These	 data	 are	
complementary	 to	 findings	 with	 pinacidil	 and	 indicate	
that	increased	IKATP	is	a	major	final	common	pathway	component	of	
the	mechanism	of	resistance	to	MI	in	AC3-I	hearts.
No improvement in mechanical function in AC3‑I hearts after 
ischemia.	Baseline	values	were	not	different	between	AC3-I,	WT	and	
AC3-C	hearts	for	LVDP,	+dP/dtmax	or	-dP/dtmax	(Fig.	7A–C).	These	
Figure 1. CaMKII inhibition enhances ischemic preconditioning. (A) Protocol for 
 ischemia‑reperfusion injury with two cycles of ischemic preconditioning (IP). Representative 
tracings from a wild type (WT) control heart are shown, where left ventricular developed 
pressure (LVDP) and the maximum contractility (+dP/dtmax) and and lusitropy (‑dP/dtmax) 
are recorded. (B) Transverse sections from WT, AC3‑I and transgenic control (AC3‑C) 
hearts stained with TCC after IP and ischemia‑reperfusion show MI as pale and viable 
myocardium as brown. (C) Summary data of MI size expressed as a percentage of total 
myocardium for WT, AC3‑I and AC3‑C hearts in the presence or absence of IP. The num‑
ber of hearts studied in each condition is shown in parentheses. In the absence of IP both 
WT and AC3‑I hearts had smaller MI size than AC3‑C (p < 0.001), but WT and AC3‑I 
MI were not significantly different (p = 0.13). In the presence of IP differences between 
all groups were significant (p < 0.001); AC3‑I MI was significantly smaller than WT MI 











-dP/dt	max	was	worse	 after	 IP	 in	AC3-C	compared	 to	WT	hearts	
(p	<	0.05),	while	there	was	no	significant	difference	between	WT	and	
AC3-I	recovery	in	the	presence	or	absence	of	IP	(Fig.	7D–F).	These	
data	 show	 that	 augmented	myocyte	 survival	 in	AC3-I	mice	 is	 not	
sufficient	for	improved	acute	recovery	after	reperfusion.
dIsCussION










IP.	 Our	 findings	 are	 consistent	 with	 cellular	 studies	 showing	 that	
simulated	 ischemia	 also	 increases	 Kir6.2	 levels	 at	 the	 membrane	
surface.20	In	contrast,	our	data	do	not	support	a	role	for	CaMKII	in	
IKATP	channel	gating.	We	cannot	 exclude	 the	possibility	 that	 some	
of	 the	 increased	 sarcolemmal	Kir6.2	was	not	 active	 in	AC3-I	 cells.	





control	 of	 the	 ischemic	 time	 and	places	 the	 entire	myocardium	 ‘at	
risk’	for	ischemia.	Interpretation	of	our	results	is	also	unencumbered	





inherent	 in	 cardiac	 excision	 and	 the	 modestly	 lower	 temperature	
during	Langendorff	perfusion	compared	to	in	vivo.	Nevertheless,	our	





Figure 2. Upregulation of IKATP in AC3‑I hearts. (A) IKATP recorded from cell 
membrane patches excised from AC3‑I, WT and AC3‑C ventricular myocytes 
under various ATP concentrations applied to the cytoplasmic membrane 
face. IKATP is ~0 pA at 1 mM ATP in each tracing. (B) Summary data show 
significantly more IKATP in AC3‑I than WT or AC3‑C ventricular myocytes 
(‡p < 0.001). (C) There were no differences in concentration dependence 
for the negative regulation of IKATP by ATP in WT (n = 8), AC3‑I (n = 10) 
and AC3‑C (n = 10) ventricular myocytes. IKATP data were normalized to the 
0 ATP condition (IKATPREL).
Figure 3. KATP channels from AC3‑I, WT and AC3‑C mice exhibit equal open 
probability in the absence of ATP. (A) Examples of the single channel record‑
ing from the AC3‑I, WT and AC3‑C cardiomyocytes. Cell membrane patches 
excised from the AC3‑I cardiomyocytes typically contained more channels 
compared to WT and AC3‑C, even though the recording was done using 
pipettes with high resistance. The calibration bars indicate 100 ms (abscissa) 
and 5 pA (ordinate). (B) Bar graphs represent calculated single channel IKATP 
open probability in WT, AC3‑C and AC3I mice. No significant differences 









Present	 findings	 in	 isolated	 hearts	 strongly	 suggest	 that	 a	
CaMKII-independent	 process(es),	 such	 as	 changes	 in	 myofilament	
Ca2+i	 sensitivity,
21	 is	 activated	 by	 ischemia	 and	 contributes	 to	
mechanical	 dysfunction	 after	 reperfusion	 using	 our	 experimental	
protocol.	 Our	 protocol	 used	 two	 cycles	 of	 IP	 prior	 to	 ischemia	
reperfusion.	This	protocol	enhanced	myocardial	survival	in	WT	and	
AC3-I	 hearts	 without	 significantly	 improving	mechanical	 function,	
consistent	 with	 other	 studies	 using	 two	 IP	 cycles.14	 On	 the	 other	
hand,	studies	with	four	IP	cycles	do	preserve	mechanical	function	in	
mouse	heart,22	suggesting	that	the	IP	benefits	to	myocardial	survival	




effect	of	 transgenic	protein	 expression	 that	
reduces	myocardial	 adaptation	 to	 ischemic	
stress.	The	findings	in	AC3-C	hearts	appear	
to	 indicate	 that	 the	 resistance	 of	 AC3-I	
hearts	 to	 MI	 after	 IP	 compared	 to	 WT	




Ischemia, Ca2+i, CaMKII and cell 
death.	Myocardial	ischemia	is	a	major	cause	
of	heart	failure	and	sudden	cardiac	death.24	
Identification	 of	 downstream	 signals	 acti-
vated	 during	 ischemia,	 therefore,	 is	 an	
important	goal	in	cardiovascular	medicine.	
CaMKII	 has	 recently	 emerged	 as	 a	 candi-
date	 for	 drug	 therapy	 in	 structural	 heart	
disease.25	CaMKII	is	activated	by	stressors,	
such	as	 isoproterenol,1	 that	 increase	Ca2+i.	
It	 is	 probably	 not	 so	 surprising,	 therefore,	
that	CaMKII	may	also	play	a	role	 in	 isch-
emia,	 which	 is	 marked	 by	 loss	 of	 Ca2+i	
homeostasis.26	AC3-I	mice	show	preserved	
cardiac	 function	 and	 Ca2+i	 homeostasis	
after	 MI	 and	 in	 response	 to	 excessive	
catecholamines.1	 CaMKII	 is	 involved	 in	
determining	 cardiomyocyte	 survival	 and	
increased	CaMKII	activity	triggers	apoptosis	
in	 response	 to	 isoproterenol	 stimulation.27	
AC3-I	mice	are	resistant	to	apoptosis	initi-
ated	 by	 isoproterenol	 or	 ischemia,2	 but	
CaMKII	inhibition	has	not	previously	been	
implicated	 in	 preventing	 cardiomyocyte	
necrosis	 in	 ischemia.	 CaMKII	 may	 also	
affect	 factors	 other	 than	 IKATP	 that	 influ-
ence	 resistance	 to	 ischemic	 stress,	 such	 as	
heart	 rate	and	SR	Ca2+	content.	However,	
our	 results	 support	 a	model	where	 cardio-
myocyte	viability	after	ischemia	is	markedly	affected	by	CaMKII	and	
where	CaMKII	inhibition	potentiates	the	beneficial	effects	of	IP.
Is CaMKII a metabolic signal in heart?	IKATP	couples	the	cellular	
energy	 charge	 to	 sarcolemmal	 repolarization28	 and	 is	 required	 for	
IP.6,29	 Our	 study	 showed	 that	 the	 mechanism	 for	 the	 benefit	 of	
CaMKII	inhibition	in	enhancing	IP	and	reducing	MI	was	post-trans-
lational	 processing	 that	 resulted	 in	 increased	 density	 of	 functional	
IKATP	channels	 in	 the	 sarcolemma.	Future	 studies	will	be	necessary	
to	 determine	 if	CaMKII	 inhibition	 directly	 affects	 IKATP	 constitu-
ents	 or	 targets	 membrane	 trafficking	 proteins	 to	 accomplish	 this	
important	task.	Ca2+i	homeostasis	is	a	significant	metabolic	expense	
in	 cardiomyocytes,	 and	 the	 reduced	 availability	 of	 ATP	 during	
ischemia	 contributes	 to	 loss	 of	 Ca2+i	 homeostasis	 and	 myocardial	
necrosis	in	MI.21	CaMKII	is	activated	by	Ca2+i	and	CaMKII	is	also	
a	 key	 regulatory	 signal	 for	 Ca2+	 homeostatic	 proteins	 in	 heart.30	
Less	is	known	about	the	role	of	CaMKII	in	myocardial	metabolism,	
but	 transient	 CaMKII	 over-expression	 in	 cardiomyocytes	 does	
Figure 4. Cardiomyocytes derived from AC3‑I mice display increased Kir6.2 membrane surface 
 expression. (A) Whole cell cardiomyocyte lysates were prepared from freshly dissociated adult mouse 
cardiomyocytes. 60 mg protein from each genotype was analyzed by SDS‑PAGE and immunoblot using 
Kir6.2, Na/Ca exchanger (NCX1) and a‑actinin (a‑act) antibodies. Protein levels from cardiomyocytes 
isolated from WT (n = 6), AC3‑C (n = 5), and AC3‑I (n = 7) hearts were averaged and expressed relative 
to WT. (B) Freshly dissociated adult cardiomyocytes were chilled to 4°C and membrane surface proteins 
were labeled with biotinylation reagent. Following membrane‑surface protein enrichment, proteins were 
analyzed by SDS‑PAGE and immunoblot. Protein levels from cardiomyocytes isolated from WT (n = 6), 
AC3‑C (n = 5), and AC3‑I (n = 7) hearts were averaged and are expressed as relative membrane surface 
expression compared to WT (p < 0.01).
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Figure 5. No changes in mRNA expression levels for genes encoding IKATP 
channel subunits. A‑D) mRNA exprression levels of (A) ABCC8 (SUR1), (B) 
ABCC9 (SUR2) (C) KCNJ8 (Kir 6.2) and (D)KCNJ11 (Kir6.2) were not 
 significantly different among the three groups. All data were normalized to 
HPRT mRNA and are averages from 4–6 hearts.
Figure 6. Increased IKATP is the mechanism for enhanced IP efficacy in AC3‑I 
hearts. Summary data for MI size in WT, AC3‑I and AC3‑C hearts treated 
with the IKATP antagonist HMR1098 (30 mM), the IKATP agonist pinacidil 
(100 mM) or vehicle during the IP and ischemia‑reperfusion protocol (Fig. 1A). 
The vehicle data were previously shown in Figure 1C. MI sizes were not 
 significantly different (p = 0.09) between groups after HMR1098. Pinacidil 
eliminated the differences in MI size between WT and AC3‑I hearts, and both 
WT and AC3‑I MI sizes were significantly less (p < 0.001) than AC3‑C after 
pinacidil. The numbers of hearts studied are given in parentheses.
Figure 7. (At left) Mechanical recovery in 
AC3‑I is not improved relative to WT and 
AC3‑C hearts after ischemia‑reperfusion injury. 
Basal mechanical properties in terms of (A). 
Left ventricular developed pressure (LVDP), (B) 
+dP/dtmax and (C) ‑dP/dtmax were similar 
in WT, AC3‑I and AC3‑C hearts. (D) LVDP 
recovery was not significantly affected by IP for 
any group. Recovery of (E) +dP/dtmax and (F) 
‑dP/dtmax were significantly less for AC3‑C, 
compared to WT, hearts after IP (*p < 0.05); 
recovery of +/‑dP/dtmax was paradoxically 
reduced (p = 0.03) in AC3‑C hearts by IP. 



















ME.	 Suppression	 of	 dynamic	 Ca2+	 transient	 responses	 to	 pacing	 in	 ventricular	 myo-
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